Upbeat call, not only in terms of impressive second quarter financial results, and in the raising of estimates for this calendar year, but in the optimism and enthusiasm from management's presentation. Analysts obviously were impressed with the quarter and the prospects for a better than expected 2014 as a whole. Optimism regarding prospects for increasing sales later this year from further penetration of the pediatric population, increasing margins from recurring use of disposables as new patients start using Dexcom CGM regularly, and the incremental international growth and the potential for further growth in the US once the Animus Vibe pump gets approval in the next few months via the marketing muscle of JNJ. Finally the optimism around the possibility of medicare coverage for CGM via congressional legislation or new clinical data persuading CMS to allow coverage of CMG as a necessary part of treatment for Type 1 DM in the medicare population, and the progress being made in using Dexcom sensors in recently presented bionic pancreas research at the ADA meetings makes the future of this company very bright. I expect upgrades and higher price targets tomorrow.